COST-EFFECTIVENESS OF SUNITINIB AS SECOND-LINE TREATMENT FOR GASTROINTESTINAL STROMAL TUMOR(GIST) IN CHINA

被引：1
|
作者：
Ren, H. [1 ]
Zhang, J. [2 ]
Dong, P. [3 ]
机构：
[1] Pfizer China, Shanghai, Peoples R China
[2] Southern Med Univ, Guangzhou, Guangdong, Peoples R China
[3] Pfizer Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1162
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN145
引用
收藏
页码：A455 / A455
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [32] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [33] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [34] Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Yang, Fan
    Fu, Yu
    Kumar, Arun
    Chen, Mingsheng
    Si, Lei
    Rojanasarot, Sirikan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (15)
  • [35] Cost-effectiveness of adjuvant imatinib in intermediate-risk gastrointestinal stromal tumors (GIST)
    Wu, Victoria S.
    Schiltz, Nicholas
    Zhao, Jack
    Winter, Jordan M.
    Hoehn, Richard S.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S265 - S265
  • [36] Second line therapies for the treatment of gastrointestinal stromal tumor
    Joensuu, Heikki
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (04) : 353 - 358
  • [37] A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    GACETA SANITARIA, 2009, 23 : 200 - 201
  • [38] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [39] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [40] ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL
    Teich, N.
    Hashizume, C.
    Follador, W.
    VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
12345